Summary
This study investigated P-REX2a protein expression in uterine endometrial malignancies, finding that elevated P-REX2a is associated with worse clinical prognosis independent of PTEN status. In vitro experiments demonstrated that P-REX2a enhances cell migration through GPCR downstream signalling pathways, implicating this protein as a potential driver of endometrial cancer progression. The findings suggest P-REX2a may be a useful prognostic marker and potential therapeutic target in endometrioid carcinomas.
UK applicability
This is a fundamental oncology research finding of potential relevance to UK diagnostic and therapeutic pathways for endometrial cancer, though application would depend on validation in independent cohorts and integration into clinical practice guidelines.
Key measures
P-REX2a immunohistochemical expression status; patient survival/prognosis outcomes; cell proliferation rates; cell migration rates; PTEN expression status
Outcomes reported
The study examined P-REX2a protein expression in 155 endometrial tumour specimens and tested its effects on cell proliferation and migration in two uterine endometrioid carcinoma cell lines. P-REX2a expression was associated with poor patient prognosis and enhanced cell motility via GPCR signalling independent of PTEN status.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.